HutchMed Raises $100 Million in Private Placement for Oncology Portfolio

Hutchison China MediTech raised $100 million in a private placement with Baring Private Equity Asia. HutchMed will use the money to develop its ten oncology assets, all of which were developed internally, for global markets. It plans to start 8-10 registration and registration-intent studies in 2021. The company has two China-approved oncology treatments, Elunate® and Sulanda®, while savolitinib is expecting approval soon. Last month, China MediTech, previously known as Chi-Med, adopted the name HutchMed. More details.... Stock Symbol: (NSDQ/AIM: HCM) Share this with colleagues: // //